Module Database Search
| MODULE DESCRIPTOR | |||
|---|---|---|---|
| Module Title | |||
| Therapeutic Delivery | |||
| Reference | PH4130 | Version | 7 |
| Created | August 2021 | SCQF Level | SCQF 10 |
| Approved | March 2013 | SCQF Points | 30 |
| Amended | August 2021 | ECTS Points | 15 |
| Aims of Module | |||
|---|---|---|---|
| To develop an understanding of the techniques pertinent to advanced drug delivery, gene technology, pharmacogenomics and proteomics and the ability to evaluate their application to the improved design, delivery and efficacy of medicinal products. | |||
| Learning Outcomes for Module | |
|---|---|
| On completion of this module, students are expected to be able to: | |
| 1 | Critically evaluate the design, formulation and application of advanced drug delivery systems for the different routes of administering medicinal products. |
| 2 | Integrate knowledge of gene structure and function into the development and application of DNA and protein technologies, biopharmaceuticals and the delivery of personalised medicine. |
| 3 | Critically appraise and discuss current trends in the advancement of targeted molecular and biological therapies; including the methods by which markers of disease and drug targets may be identified. |
| 4 | Apply knowledge of established and novel drug delivery systems to investigate the development of emerging therapeutics and communicate this information. |
| 5 | Demonstrate knowledge and understanding of DNA separation tehcniques and gene cloning. |
| Indicative Module Content |
|---|
| Delivering therapeutics in a way that is right for the patient; safe, painless, reliable, targeted and efficient. Topics include: Design and formulation of delivery systems for parenteral, oral, buccal, nasal, pulmonary, ocular and transdermal delivery; Drug targeting and controlled release of chemical molecules, peptides and proteins; Novel approaches to antimicrobial chemotherapy; Production of recombinant DNA and genetically engineered medicines; Principles and applications of gene therapy; Role of pharmacogenomics in the delivery of personalized medicine; Genomic and proteomic screening for disease diagnosis and identification of drug targets; Mechanism of action and use of immunotherapies. |
| Module Delivery |
|---|
| Lectures (including delivery by external industrialists), coursework sessions (including laboratory based group mini-projects and workshops), tutorials, directed study, PCCAL, self-assessment (quizzes) and problem solving. |
| Indicative Student Workload | Full Time | Part Time |
|---|---|---|
| Contact Hours | 65 | N/A |
| Non-Contact Hours | 235 | N/A |
| Placement/Work-Based Learning Experience [Notional] Hours | N/A | N/A |
| TOTAL | 300 | N/A |
| Actual Placement hours for professional, statutory or regulatory body |
| ASSESSMENT PLAN | |||||
|---|---|---|---|---|---|
| If a major/minor model is used and box is ticked, % weightings below are indicative only. | |||||
| Component 1 | |||||
| Type: | Examination | Weighting: | 60% | Outcomes Assessed: | 1, 2, 3, 5 |
| Description: | Component 1 is a 3 hour written exam. | ||||
| Component 2 | |||||
| Type: | Coursework | Weighting: | 40% | Outcomes Assessed: | 4 |
| Description: | Component 2 is an individual report (in a poster format) of a group project. | ||||
| MODULE PERFORMANCE DESCRIPTOR | |
|---|---|
| Explanatory Text | |
| The first grade represents Component 1 (EX1) weighted as major and the second, Component 2 (CW1), weighted as minor. A minimum of Grade D or better is required to pass the module. Non-submission of either component will result in an NS grade. | |
| Module Grade | Minimum Requirements to achieve Module Grade: |
| A | AA,AB |
| B | BA,BB,BC,AC,AD,CA |
| C | CB,CC,CD,BD,DA,DB |
| D | DC,DD |
| E | EA,EB,EC,ED,EE,AE,BE,CE,DE,AF,BF,CF,DF,FA,FB,FC |
| F | FD,FE,FF,EF |
| NS | Non-submission of work by published deadline or non-attendance for examination |
| Module Requirements | |
|---|---|
| Prerequisites for Module | Successful completion of MPharm stage 2. |
| Corequisites for module | None. |
| Precluded Modules | None. |
| INDICATIVE BIBLIOGRAPHY | |
|---|---|
| 1 | NELSON, D.L. and COX, M.M. Lehninger: Principles of Biochemistry. Current edition. New York, Worth Publishers. TURNER, P.C., MCLENNAN, A.G., BATES, A.D. and WHITE, M.R.H. Instant notes:Molecular Biology. Current edition. Oxford,Bios Scientific Publishers Ltd. ALLEN, L.V., POPOVICH, N.G. and ANSEL, H.C. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Current edition. Philidelphia, Lippincott Williams & Wilkins. ARMSTRONG, N.A. and JAMES, K.C. Pharmaceutical Experimental Design and Interpretation. London, Taylor and Francis. AULTON, M.E., (ed.) Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Current edition. London, Churchill Livingstone. SINKO, P.J. Martin's Physical Pharmacy and Pharmaceutical Sciences. Current edition. Lippincott Williams & Wilkins. |
| 2 | TURNER, P.C., MCLENNAN, A.G., BATES, A.D. and WHITE, M.R.H. Instant Notes: Molecular Biology. Current Edition. Oxford: Bios Scientific Publishers Limited. |
| 3 | ALLEN, L.V., POPOVICH, N.G. and ANSEL, H.C. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Current edition. Philidelphia: Lippincott Williams & Wilkins. |
| 4 | ARMSTRONG, N.A. and JAMES, K.C. Pharmaceutical Experimental Design and Interpretation. London: Taylor and Francis. |
| 5 | AULTON, M.E., ed. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Current edition London: Churchill Livingstone. |
| 6 | SINKO, P.J. Martin's Physical Pharmacy and Pharmaceutical Sciences. Current edition. Lippincott Williams & Wilkins. |